Your browser doesn't support javascript.

Biblioteca Virtual em Saúde


Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity.

Abdelsalam, Mostafa; Elmorsy, Ekramy; Abdelwahab, Hassan; Algohary, Osman; Naguib, Mahmoud; El Wahab, Ahmed Abd; Eldeeb, Ahmed; Eltoraby, Ehab; Abdelsalam, Adel; Sabry, Alaa; El-Metwally, Mohamed; Akl, Mohamed; Anber, Nahla; El Sayed Zaki, Maysaa; Almutairi, Fahad; Mansour, Tamer.
BMC Nephrol; 19(1): 219, 2018 09 04.
Artigo em Inglês | MEDLINE | ID: mdl-30180818


Nephrotoxicity is a major hazard complicating the use of platinum based drugs (PBD), which can hinder using higher doses protocols to maximize the therapeutic gain. Shortage of serum creatinine level as an accurate biomarker for acute kidney injuries (AKI) necessitates searching for novel biomarkers with better sensitivity and specificity in patients on PBD.


In a prospective cohort design, 132 patients receiving PBD were selected for the study. AKI was diagnosed by continuous follow up of serum creatinine level according to Kidney Disease Improving Global Outcomes (KDIGO) guidelines 2012. Serum creatinine and urinary biomarkers (KIM-1, NGAL and cystatin C) was measured in the day of treatment and for 3 days after PBD cycle.


AKI occurred in 35 patients (26.52% of patients). KIM-1, Cystatin C, and NGAL showed significant increase in samples collected in the day of AKI in comparison to their corresponding basal levels (P <  0.0001). In addition, significant increase in urinary levels of the biomarkers in samples collected 1 day before AKI in comparison to their basal levels (P <  0.0001, P <  0.0001, and P = 0.013 for KIM-1, NGAL and Cystatin C respectively). Furthermore KIM-1 data showed a significant increase 2 days before serum creatinine rise in comparison to the corresponding KIM-1 levels in patients who developed AKI (P = 0.001).


Urinary KIM-1, Cystatin C and NGAL can predict PBD induced AKI in earlier stages than serum createnine. KIM-1 is the most sensitive biomarker for early detection of AKI in patients receiving PBD.
Selo DaSilva